Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial
The Oncologist · 2024
DOI: 10.1093/oncolo/oyad348 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Kathryn E Beckermann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Renal Cell, Kidney Neoplasms, Quinolines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AVEO Pharmaceuticals, Inc.
Abstract (Originalsprache)
Background
Tivozanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) with efficacy in advanced renal cell carcinoma (RCC). Long-term exploratory analyses from the TIVO-3 trial in relapsed/refractory (R/R) RCC including patients (26%) with prior immuno-oncology (IO) therapy are reported.
Methods
Patients with R/R advanced RCC that progressed with 2 or 3 prior systemic therapies (≥1 VEGFR TKI) were randomized to tivozanib 1.5 mg QD or sorafenib 400 mg BID, stratified by IMDC risk and previous therapy. Safety, investigator-assessed long-term progression-free survival (LT-PFS), and serial overall survival (OS) were assessed.
Results
Mean time on treatment was 11.0 months with tivozanib (n = 175) and 6.3 months with sorafenib (n = 175). Fewer grade ≥3 treatment-related adverse events occurred with tivozanib (46%) than sorafenib (55%). Dose modification rates were lower with tivozanib than sorafenib across age/prior IO subgroups; prior IO therapy did not impact dose reductions or discontinuations in either arm. Landmark LT-PFS rates were higher with tivozanib (3 years: 12.3% vs 2.4%; 4 years: 7.6% vs 0%). After 22.8 months mean follow-up, the OS HR was 0.89 (95% CI, 0.70-1.14); when conditioned on 12-month landmark PFS, tivozanib showed significant OS improvement over sorafenib (HR, 0.45; 95% CI, 0.22-0.91; 2-sided P = .0221).
Conclusions
Tivozanib demonstrated a consistent safety profile and long-term survival benefit in patients with R/R advanced RCC who were alive and progression free at 12 months. These post hoc exploratory analyses of LT-PFS and conditional OS support a clinically meaningful improvement with tivozanib versus sorafenib in this advanced RCC population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
- Clinical Development and Medical Affairs, AVEO Oncology, Boston, MA, USA.
- Department of Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
- Department of Medical Oncology, Gustave Roussy, Villejuif, France.
- Texas A&M College of Medicine, Bryan, TX, USA.
- Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA, USA.
ORCID-Profile: Kathryn E Beckermann, Michael B Atkins, Brian I Rini
Förderung
- AVEO Pharmaceuticals, Inc
Zitieren
APA
Beckermann, K. E., Asnis-Alibozek, A. G., Atkins, M. B., Escudier, B., Hutson, T. E., Kasturi, V., McDermott, D. F., Pal, S. K., Porta, C., Rini, B. I., & Verzoni, E. (2024). Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The Oncologist. https://doi.org/10.1093/oncolo/oyad348
Vancouver
Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, et al. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The Oncologist. 2024. doi:10.1093/oncolo/oyad348
BibTeX
@article{Beckermann2024,
author = {Beckermann, Kathryn E and Asnis-Alibozek, Aviva G and Atkins, Michael B and Escudier, Bernard and Hutson, Thomas E and Kasturi, Vijay and McDermott, David F and Pal, Sumanta K and Porta, Camillo and Rini, Brian I and Verzoni, Elena},
title = {Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyad348}
}
EUVIMED